Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation
- PMID: 8892106
- DOI: 10.1002/(SICI)1097-4547(19961001)46:1<58::AID-JNR8>3.0.CO;2-E
Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation
Abstract
The aggregation of amyloid beta peptide (A beta) into its fibrillar, cross beta-pleated configuration is generally viewed as a critical event in the pathophysiology of Alzheimer's disease (AD). A diverse group of molecules, the A beta binding proteins, has been evaluated for their effects on this process. However, most of these studies have used micromolar or greater reagent concentrations, and their different methods have not permitted quantitative comparisons of the efficacy of different A beta binding proteins in augmenting or inhibiting aggregation. In the present work we have undertaken a coherent analysis using fluorimetry of thioflavin T-stained experimental solutions. The complement protein C1q, serum amyloid P, and transthyretin significantly enhanced the formation of precipitable, cross beta-pleated aggregates in solutions of 800 nM A beta 1-42. Under these same experimental conditions, alpha 1-antichymotrypsin had no significant effect on the aggregation process, and both the E3 and E4 isoforms of apolipoprotein E were significant inhibitors. There was a non-significant trend toward the E3 isoform exhibiting greater inhibition than the E4 isoform. Of the aggregation-facilitating molecules, C1q was substantially and significantly the most potent.
Similar articles
-
Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide.Am J Pathol. 1997 May;150(5):1531-6. Am J Pathol. 1997. PMID: 9137079 Free PMC article.
-
Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation.Biochem Biophys Res Commun. 1995 Dec 26;217(3):869-75. doi: 10.1006/bbrc.1995.2852. Biochem Biophys Res Commun. 1995. PMID: 8554610
-
Amyloid P component and other acute-phase proteins associated with cerebellar A beta-deposits in Alzheimer's disease.Brain Res. 1993 Dec 17;631(1):151-5. doi: 10.1016/0006-8993(93)91202-4. Brain Res. 1993. PMID: 7507788
-
[Amyloid-selective Photooxygenation toward Treatment for Amyloid Diseases].Yakugaku Zasshi. 2018;138(1):47-53. doi: 10.1248/yakushi.17-00186-2. Yakugaku Zasshi. 2018. PMID: 29311465 Review. Japanese.
-
[Apolipoprotein E4 and late-onset Alzheimer's disease].Nihon Rinsho. 1994 Dec;52(12):3257-65. Nihon Rinsho. 1994. PMID: 7853720 Review. Japanese.
Cited by
-
Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide.Am J Pathol. 1997 May;150(5):1531-6. Am J Pathol. 1997. PMID: 9137079 Free PMC article.
-
Inhibition of TTR aggregation-induced cell death--a new role for serum amyloid P component.PLoS One. 2013;8(2):e55766. doi: 10.1371/journal.pone.0055766. Epub 2013 Feb 4. PLoS One. 2013. PMID: 23390551 Free PMC article.
-
Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer's disease cognition.Alzheimers Res Ther. 2022 Jun 29;14(1):88. doi: 10.1186/s13195-022-01020-9. Alzheimers Res Ther. 2022. PMID: 35768831 Free PMC article.
-
Apolipoprotein ε7 allele in memory complaints: insights through protein structure prediction.Clin Interv Aging. 2017 Jul 11;12:1095-1102. doi: 10.2147/CIA.S131172. eCollection 2017. Clin Interv Aging. 2017. PMID: 28744113 Free PMC article.
-
The binding of apolipoprotein E to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation.Biochemistry. 2014 Oct 14;53(40):6323-31. doi: 10.1021/bi5008172. Epub 2014 Sep 25. Biochemistry. 2014. PMID: 25207746 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials